Literature DB >> 8567892

Torulopsis glabrata: azole susceptibilities by microdilution colorimetric and macrodilution broth assays.

R N Tiballi1, L T Zarins, X He, C A Kauffman.   

Abstract

Fluconazole and itraconazole MICs were determined by both the standard macrodilution method of the National Committee for Clinical Laboratory Standards and a colorimetric broth microdilution method for 140 isolates of Torulopsis (Candida) glabrata obtained over a 15-year period. Using the method of the National Committee for Clinical Laboratory Standards the MICs at which 90% of isolates are inhibited (MIC50) for all isolates were 32 and 1.6 micrograms/ml for fluconazole and itraconazole, respectively. For fluconazole, the MIC90 rose from 16 to > 64 micrograms/ml when the MIC90s for isolates collected from July 1980 to June 1991 were compared with those for isolates collected from July 1991 to March 1995. For itraconazole, the MIC90s for isolates from the same time periods were 0.8 and 3.2 micrograms/ml, respectively. Although for isolates from some non-human immunodeficiency virus-infected patients the MICs rose, most of the high MICs were found for isolates from human immunodeficiency virus-infected patients who had been extensively treated with azole drugs for thrush. The colorimetric method yielded endpoints that were more definitive; concordances within 2 dilutions for the two methods were 87% for fluconazole and 86% for itraconazole.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8567892      PMCID: PMC228540          DOI: 10.1128/jcm.33.10.2612-2615.1995

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  26 in total

1.  Ketoconazole resistance in Torulopsis glabrata.

Authors:  G Nobre; E Mendes; M J Charrua; O Cruz
Journal:  Mycopathologia       Date:  1989-07       Impact factor: 2.574

2.  Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole.

Authors:  J R Wingard; W G Merz; M G Rinaldi; T R Johnson; J E Karp; R Saral
Journal:  N Engl J Med       Date:  1991-10-31       Impact factor: 91.245

3.  Fluconazole resistance in Candida glabrata.

Authors:  D W Warnock; J Burke; N J Cope; E M Johnson; N A von Fraunhofer; E W Williams
Journal:  Lancet       Date:  1988-12-03       Impact factor: 79.321

Review 4.  Antifungal susceptibility testing.

Authors:  J H Rex; M A Pfaller; M G Rinaldi; A Polak; J N Galgiani
Journal:  Clin Microbiol Rev       Date:  1993-10       Impact factor: 26.132

Review 5.  Susceptibility testing of fungi: current status of the standardization process.

Authors:  J N Galgiani
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

6.  Efficacy of ketoconazole v nystatin in prevention of fungal infections in neutropenic patients.

Authors:  P G Jones; C A Kauffman; L S McAuliffe; M K Liepman; A G Bergman
Journal:  Arch Intern Med       Date:  1984-03

7.  Fluconazole resistance in Candida glabrata.

Authors:  C A Hitchcock; G W Pye; P F Troke; E M Johnson; D W Warnock
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

8.  Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients.

Authors:  J R Wingard; W G Merz; M G Rinaldi; C B Miller; J E Karp; R Saral
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

9.  Management of persistent vulvo vaginal candidosis due to azole-resistant Candida glabrata.

Authors:  D J White; E M Johnson; D W Warnock
Journal:  Genitourin Med       Date:  1993-04

10.  Characterization of an azole-resistant Candida glabrata isolate.

Authors:  H vanden Bossche; P Marichal; F C Odds; L Le Jeune; M C Coene
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

View more
  5 in total

1.  Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group.

Authors:  P Phillips; S Shafran; G Garber; C Rotstein; F Smaill; I Fong; I Salit; M Miller; K Williams; J M Conly; J Singer; S Ioannou
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-05       Impact factor: 3.267

2.  Comparison of rapid testing methods for enzyme production with the germ tube method for presumptive identification of Candida albicans.

Authors:  J S Heelan; D Siliezar; K Coon
Journal:  J Clin Microbiol       Date:  1996-11       Impact factor: 5.948

3.  Detection of Candida dubliniensis in oropharyngeal samples from human immunodeficiency virus-infected patients in North America by primary CHROMagar candida screening and susceptibility testing of isolates.

Authors:  W R Kirkpatrick; S G Revankar; R K Mcatee; J L Lopez-Ribot; A W Fothergill; D I McCarthy; S E Sanche; R A Cantu; M G Rinaldi; T F Patterson
Journal:  J Clin Microbiol       Date:  1998-10       Impact factor: 5.948

Review 4.  Antifungal agents in the 1990s. Current status and future developments.

Authors:  C A Kauffman; P L Carver
Journal:  Drugs       Date:  1997-04       Impact factor: 9.546

5.  Comparison of a photometric method with standardized methods of antifungal susceptibility testing of yeasts.

Authors:  C J Clancy; M H Nguyen
Journal:  J Clin Microbiol       Date:  1997-11       Impact factor: 5.948

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.